News Pfizer's fast-tracked leukaemia candidate could rival CAR-Ts Antibody-drug conjugate with FDA gets six-month review.
News Amgen/UCB reveal new osteoporosis drug data But romosozumab missed secondary endpoint of non-vertebral fractures
Articles Stop being control freaks: pharma’s challenge in involving p... Lode Dewulf, chief patient affairs officer at UCB, tells Paul Tunnah how patient-centricity is evolving, and describes how pharma still needs to adapt.
Articles UCB: growing sales and growing bones The specialist pharma company is set to expand into osteoporosis through its partnership with Amgen
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
